BANK OF AMERICA CORP /DE/ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 18 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q4 2021$1,926,000
-53.5%
2,000,000
-55.6%
0.00%
Q3 2021$4,139,000
+327.1%
4,500,000
+350.0%
0.00%
Q1 2019$969,000
+888.8%
1,000,000
+1150.0%
0.00%
Q3 2017$98,00080,0000.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2017
NameSharesValueWeighting ↓
Context Capital Management, LLC 6,000,000$5,827,0003.55%
DeepCurrents Investment Group LLC 21,223,000$20,803,0001.80%
ZAZOVE ASSOCIATES LLC 19,230,000$18,725,0001.77%
Mohican Financial Management, LLC 500,000$494,0001.61%
Castle Creek Arbitrage, LLC 5,149,000$5,015,0001.47%
LINDEN ADVISORS LP 62,688,000$61,071,0001.40%
Verition Fund Management LLC 10,817,000$10,504,0000.41%
WOLVERINE ASSET MANAGEMENT LLC 24,100,000$23,451,0000.32%
Baupost Group 30,000,000$29,213,0000.24%
SSI INVESTMENT MANAGEMENT LLC 2,763,000$2,676,0000.22%
View complete list of THERAVANCE BIOPHARMA INC shareholders